Table 1.

Prescription omega-3 fatty acids.

Formulation	Product	EPA/DHA composition	Dose	Indication
Icosapent ethyl (ethyl ester of EPA)	Vascepaa (US) [14]	1-g capsules containing 998 mg icosapent ethyl	2 × 1-g capsules twice daily with or following a meal	To reduce the risk of CV events in adult statin-treated patients with elevated TG (≥150 mg/dL) and established CV disease, or diabetes and at least two other CV risk factors
	Vazkepa (EU) [12]			To reduce the risk of CV events in adult statin-treated patients at high CV risk with elevated TG (≥150 mg/dL) and established CV disease, or diabetes and at least one other CV risk factor
Omega-3-ethyl esters	Lovaza (US) [15]b	1-g capsules containing ≥900 mg PUFA, including EPA 460 mg and DHA 380 mg	4 capsules daily	To reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia in adjunct to diet
	Omacor (EU) [13]c		2–4 capsules daily	Treatment of endogenous hypertriglyceridemia as a supplement to diet when dietary measures alone are insufficient to produce an adequate response: as monotherapy or in combination with statins when control of TG is insufficient

CV, cardiovascular; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; EU, European Union; PUFA, polyunsaturated fatty acid; TG, triglycerides; US, United States.

^aGeneric versions of Vascepa are available in the US; these generic versions are approved for treatment of severe hypertriglyceridemia (≥500 mg/dL) only.

^bGeneric versions of Lovaza are available in the US.

^cGeneric versions of Omacor are available in the EU.